Sanofi Says MS Pill Aubagio Fails to Beat Rebif in Trial
This article is for subscribers only.
Sanofi, France’s biggest drugmaker, said its experimental pill Aubagio for the treatment of multiple sclerosis failed to beat an older injected therapy at preventing relapses or keeping patients on treatment.
Aubagio, whose chemical name is teriflunomide, showed no statistical superiority to Merck KGaA’s medicine Rebif, Paris-based Sanofi said in an e-mailed statement today. The late-stage trial, dubbed Tenere, showed Aubagio was safe and well tolerated, Sanofi said.